Collaborations & Alliances
Related Searches:
Filter by:
751 - 765 of 1093 results
March 30, 2009
Patheon has entered an alliance with Swiftwater Group, LLC to provide regulatory consulting services to clients.
Read More »
March 23, 2009
BioDuro and AstraZeneca have expanded their discovery research collaboration for respiratory and inflammation indications.
Read More »
March 16, 2009
ICON and MedAvante, Inc., a provider of centralized psychiatric patient evaluation, have signed an alliance agreement combining ICON's global reach and expertise in clinical trial management with MedAvante's platform to centralize and calibrate the assess
Read More »
March 10, 2009
Pepscan Therapeutics has earned a milestone payment from Genmab from an ongoing research collaboration aimed at identifying human antibodies against intractable targets.
Read More »
March 5, 2009
Bristol-Myers Squibb entered a global collaboration with Nissan Chemical Industries, Ltd. and Teijin Pharma Ltd. for the development and commercialization of NTC-801, a selective inhibitor of the acetylcholine-activated potassium ion channel (IKACh), curr
Read More »
February 27, 2009
Cyclogenix has entered into license and research agreements with Wyeth Pharmaceuticals and IMBcom, The University of Queensland’s (UQ) company for commercializing technology from the Institute for Molecular Bioscience (IMB).
Read More »
February 23, 2009
Xencor, Inc. has entered into an antibody optimization collaboration with CSL, Ltd., under which CSL will have access to Xencor’s XmAb technology platform to enhance the ADCC effector function of its therapeutic antibodies.
Read More »
January 29, 2009
Argenta Discovery Ltd. and Zafgen, Inc. have entered a drug discovery collaboration to develop one of Zafgen’s therapeutics programs for obesity.
Read More »
January 19, 2009
Galapagos NV has expanded its anti-infectives alliance with GlaxoSmithKline to include three more discovery targets. Galapagos will receive a payment of $2.7 million from GSK.
In December 2007, the two companies initiated a program to discover an…
Read More »
January 14, 2009
PPD, Inc. has expanded its post-approval drug safety expertise in epidemiology and risk management through a strategic alliance with World Health Information Science Consultants (WHISCON), an epidemiology and drug-safety organization based in Wellesl…
Read More »
January 13, 2009
Bristol-Myers Squibb and ZymoGenetics, Inc. entered a global collaboration for PEG-Interferon lambda, a novel type 3 interferon currently in Phase Ib development for the treatment of Hepatitis C, and its related development program.
Under the term…
Read More »
January 12, 2009
Wyeth and Santaris Pharma have entered into a worldwide strategic alliance to discover, develop and commercialize new medicines based on Santaris' Locked Nucleic Acid (LNA) drug platform, which allows specific targeting and regulation of microRNAs (m…
Read More »
January 9, 2009
XDx, Inc. has signed a collaborative pharmacogenomics agreement with Bristol-Myers Squibb focused on identifying biomarkers for Systemic Lupus Erythematosus (SLE) for clinical diagnostic purposes associated with the development of BMS' rheumatoid art…
Read More »
January 6, 2009
Galapagos NV has successfully achieved a pre-clinical candidate drug in its osteoarthritis alliance with GlaxoSmithKline. Galapagos also reached milestones on other compounds in the alliance, earning milestone payments totaling $10.5 million. Under t…
Read More »
January 5, 2009
PPD, Inc. has purchased Merck’s 130,000-sq.-ft. vaccine testing lab and related equipment in Wayne, PA and hired the 80 Merck employees who operate the facility. PPD will provide assay development and immunogenicity testing services to support…
Read More »
751 - 765 of 1093 results
